Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Conditions

• Chronic Spontaneous Urticaria

Eligibility Criteria

Sex

ALL

Age

18 Years - 99 Years

Healthy Volunteers

Not accepted

Interventions

• Remibrutinib — DRUG
  Remibrutinib should be taken in accordance with the recommendations in the treatment plan.

Study Details

The purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide access to remibrutinib for adult patients with chronic spontaneous urticaria (CSU)

Key Dates

Status verified

Dec 2025

Central Contacts

• MAP requests are initiated by a licensed physician.https:// www.novart is.com/healthcare-professionals/managed-access-programs
  1-888-669-6682
  [email protected]
• Novartis Pharmaceuticals

Related Studies

• 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
  PHASE3 · Recruiting · Novartis Pharmaceuticals · Bakersfield, California
• Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
  PHASE2 · Recruiting · Blueprint Medicines Corporation · Birmingham, Alabama
• A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
  PHASE2 · Recruiting · Pfizer · Little Rock, Arkansas
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
  PHASE3 · Enrolling By Invitation · Celldex Therapeutics · Birmingham, Alabama